DNLI - Company ID 0001714899
The table below shows Denali Therapeutics Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $102.87M | $201.53M | $387.63M | $90.96M | $141.21M | $56.95M |
| Short-term investments | $413.33M | $508.94M | $600.06M | $757.24M | $757.75M | $760.98M |
| Receivables | $18.88M | $3.93M | - | - | - | - |
| Inventory | $26.27M | $4.14M | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $591.71M |
| $753.93M |
| $1.02B |
| $882.60M |
| $934.71M |
| $878.64M |
| Property, plant & equipment | $47.91M | $49.93M | $51.73M | $53.73M | $58.72M | $57.77M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $1.26B | $1.16B | $1.27B | $1.06B | $1.17B | $1.27B |
| Accounts payable | $13.70M | $11.81M | $40.38M | $6.75M | $10.84M | $8.46M |
| Total current liabilities | $95.26M | $90.08M | $110.16M | $90.15M | $91.06M | $91.88M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $329.65M | $322.78M | $339.93M | $129.42M | $139.19M | $148.66M |
| Retained earnings | -$2.24B | -$2.31B | -$2.18B | -$1.92B | -$1.80B | -$1.67B |
| Total equity | $926.39M | $835.18M | $926.10M | $926.20M | $1.03B | $1.12B |